

File No. ED/Misc-273/2020-3
Government of India
Directorate of Health Services
Central Drugs Standard Control Organization
(Enforcement Division)

FDA Bhawan Kotla Road
New Delhi – 110 002
Dated 10.04.2021

To

All State/UT Drugs Controllers

Subject: Enforcement activities to stop hoarding/black marketing/overcharging of COVID management drug Remdesivir - Regarding

Sir/Madam

It has been brought to the notice of this office that many family members of COVID-19 patients have raised concerns highlighting that Remdesivir is once again being sold above MRP and in some cases as high as over 10 times.

In light of reports of shortages of Remdesivir Ministry of Health and Family Welfare, Government of India have also communicated to the State/UT Governments regarding various steps initiated including direction already given to enforcement staff/Drugs Inspectors to verify stocks and check other malpractices and also take other effective action to curb hoarding and black marketing with request to review this with the Drugs Inspectors in the States/UTs.

In view of above, you are requested to instruct your enforcement staff immediately to keep strict vigil especially at sensitive places and to take stringent action against hoarding/black marketing/overcharging for Remdesivir, by conducting the special drive of monitoring and investigation, so that any such incidence for the drug is prevented.

Action taken in the matter may please be intimated to this office at the earliest.

Yours Faithfully



(Dr. V. G. Somani)
Drugs Controller General (India)

Copy to:

1. All Zonal/SubZonal offices of CDSCO – For immediate action in the matter

Copy for information to:

1. Chairman, NPPA
2. PS to JS (R), Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi – 110 011